Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 678 participants.
Also called NCT02348723
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 678 participants
- Sponsor
- Registry
-
NCT02348723 -
2014-003890-40
-
- Other papers using this trial's data
- Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study
- Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, Russia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02348723. Randomized; no masking; primary purpose treatment. Start 2015-04-28 (actual); primary completion 2016-11-11 (actual). Results posted on 2017-11-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Warfarin
- Intervention (Drug)
- Dabigatran Etexilate 150mg
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct02348723- Content hash
d300b625603a3b2d9ee2778ea6252f6b6dc90c52cc15d42c7708a1aeeb3c25d1